Aurinia Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Aurinia Pharmaceuticals has a total shareholder equity of $388.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $549.4M and $161.4M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$348.24m |
| Equity | US$388.00m |
| Total liabilities | US$161.36m |
| Total assets | US$549.36m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: IKAP's short term assets ($440.5M) exceed its short term liabilities ($78.6M).
Long Term Liabilities: IKAP's short term assets ($440.5M) exceed its long term liabilities ($82.8M).
Debt to Equity History and Analysis
Debt Level: IKAP is debt free.
Reducing Debt: IKAP had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable IKAP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: IKAP is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.7% per year.